Literature DB >> 16898809

C6-substituted analogues of 8-azanebularine: probes of an RNA-editing enzyme active site.

Olena Maydanovych1, Peter A Beal.   

Abstract

[reaction: see text] We describe the synthesis of derivatives of 8-azanebularine, a known inhibitor of adenosine deaminases including the RNA-editing enzyme ADAR2. 6-Methyl, 6-hydroxymethyl, 6-cyano, and 6-mercapto derivatives were obtained from 6-bromo precursors using different cross-coupling or substitution reactions. The C6-methyl derivative was incorporated into an RNA substrate for ADAR2 via the phosphoramidite. Quantitative gel mobility shift experiments with the resulting RNA indicate that methylation at C6 dramatically reduces the affinity of 8-azanebularine for ADAR2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898809     DOI: 10.1021/ol061354j

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  5 in total

Review 1.  Novel modifications in RNA.

Authors:  Kelly Phelps; Alexi Morris; Peter A Beal
Journal:  ACS Chem Biol       Date:  2011-12-23       Impact factor: 5.100

Review 2.  Nucleoside analogs in the study of the epitranscriptome.

Authors:  Cody M Palumbo; Peter A Beal
Journal:  Methods       Date:  2018-10-26       Impact factor: 3.608

3.  The loss of a hydrogen bond: Thermodynamic contributions of a non-standard nucleotide.

Authors:  Elizabeth A Jolley; Brent M Znosko
Journal:  Nucleic Acids Res       Date:  2017-02-17       Impact factor: 16.971

4.  Recognition of duplex RNA by the deaminase domain of the RNA editing enzyme ADAR2.

Authors:  Kelly J Phelps; Kiet Tran; Tristan Eifler; Anna I Erickson; Andrew J Fisher; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2015-01-06       Impact factor: 16.971

5.  Nucleoside analog studies indicate mechanistic differences between RNA-editing adenosine deaminases.

Authors:  Rena A Mizrahi; Kelly J Phelps; Andrea Y Ching; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2012-08-11       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.